Bevacizumab for neovascular age related macular degeneration (ABC Trial): Multicentre randomised double masked study

BMJ (Online)

Volumn 340, Issue 7761, 2010, Pages 1398-

  Tufail, Adnan ^a   Patel, Praveen J ^a   Egan, Catherine ^a   Hykin, Philip ^a   Da Cruz, Lyndon ^a   Gregor, Zdenek ^a   Dowler, Jonathan ^a   Majid, Mohammed A ^b   Bailey, Clare ^b   Mohamed, Quresh ^c   Johnston, Robert ^c   Bunce, Catey ^a   Xing, Wen ^a  

^a MOORFIELDS EYE HOSPITAL   (United Kingdom)

^b BRISTOL EYE HOSPITAL   (United Kingdom)

^c CHELTENHAM GENERAL HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

BEVACIZUMAB; PEGAPTANIB; VERTEPORFIN;

AGED; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG SAFETY; ENDOPHTHALMITIS; EYE INFLAMMATION; FEMALE; HUMAN; INTERVENTION STUDY; INTRAOCCULAR INFLAMMATION; IRIDOCYCLITIS; IRITIS; LENS DISEASE; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; NEOVASCULAR AGE RELATED MACULAR DEGENERATION; PATIENT CARE; PHOTODYNAMIC THERAPY; PRIORITY JOURNAL; PROSPECTIVE STUDY; RANDOMIZED CONTROLLED TRIAL; RETINA DETACHMENT; RETINA MACULA AGE RELATED DEGENERATION; RETINA TEAR; RHEGMATOGENOUS RETINAL DETACHMENT; TREATMENT OUTCOME; UVEITIS; VISUAL ACUITY; VITREOUS HEMORRHAGE; VITRITIS;

AGED; AGED, 80 AND OVER; ANGIOGENESIS INHIBITORS; ANTIBODIES, MONOCLONAL; ANTIBODIES, MONOCLONAL, HUMANIZED; CHOROIDAL NEOVASCULARIZATION; DOUBLE-BLIND METHOD; FEMALE; HUMANS; INJECTIONS, INTRAVENOUS; MACULAR DEGENERATION; MALE; MIDDLE AGED; PROSPECTIVE STUDIES; TREATMENT OUTCOME; VISUAL ACUITY;

EID: 77954106891     PISSN: None     EISSN: 17561833     Source Type: Journal    
DOI: 10.1136/bmj.c2459     Document Type: Article

References (34)

1. Klein R, Klein BE, Jensen SC, Mares-Perlman JA, Cruickshanks KJ, Palta M. Age-related maculopathy in a multiracial United States population: the National Health and Nutrition Examination Survey III. Ophthalmology 1999;106:1056-65.
2. Friedman DS, O'Colmain BJ, Munoz B, Tomany SC, McCarty C, de Jong PT, et al. Prevalence of age-relatedmacular degeneration in the United States. Arch Ophthalmol 2004;122:564-72.
3. Photodynamic therapy of subfoveal choroidal neovascularization in age-related macular degeneration with verteporfin: one-year results of 2 randomized clinical trials - TAP report. Treatment of age-related macular degenerationwith photodynamic therapy (TAP) study group. Arch Ophthalmol 1999;117:1329-45.
4. Bressler NM. Photodynamic therapy of subfoveal choroidal neovascularization in age-related macular degeneration with verteporfin: two-year results of 2 randomized clinical trials - TAP report 2. Arch Ophthalmol 2001;119:198-207.
5. Gragoudas ES, Adamis AP, Cunningham ET Jr, Feinsod M, Guyer DR. Pegaptanib for neovascular age-related macular degeneration. N Engl J Med 2004;351:2805-16.
6. Hurwitz H, Fehrenbacher L, Novotny W, Cartwright T, Hainsworth J, Heim W, et al. Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med 2004;350:2335-42.
7. Rosenfeld PJ, Moshfeghi AA, Puliafito CA. Optical coherence tomography findings after an intravitreal injection of bevacizumab (avastin) for neovascular age-related macular degeneration. Ophthalmic Surg Lasers Imaging 2005;36:331-5.
8. Avery RL, Pieramici DJ, Rabena MD, Castellarin AA, Nasir MA, Giust MJ. Intravitreal bevacizumab (avastin) for neovascular age-related macular degeneration. Ophthalmology 2006;113:363-72.
9. Spaide RF, Laud K, Fine HF, Klancnik JM Jr, Meyerle CB, Yannuzzi LA, et al. Intravitreal bevacizumab treatment of choroidal neovascularization secondary to age-related macular degeneration. Retina 2006;26:383-90.
10. Rosenfeld PJ, Brown DM, Heier JS, Boyer DS, Kaiser PK, Chung CY, et al. Ranibizumab for neovascular age-related macular degeneration. N Engl JMed 2006;355:1419-31.
11. Brown DM, Kaiser PK, Michels M, Soubrane G, Heier JS, Kim RY, et al. Ranibizumab versus verteporfin for neovascular age-relatedmacular degeneration. N Engl JMed 2006;355:1432-44.
12. Schouten JS, La Heij EC, Webers CA, Lundqvist IJ, Hendrikse F. A systematic review on the effect of bevacizumab in exudative age-related macular degeneration.Graefes Arch Clin Exp Ophthalmol 2009;247:1-11.
13. Ziemssen F, Grisanti S, Bartz-Schmidt KU, Spitzer MS. Off-label use of bevacizumab for the treatment of age-relatedmacular degeneration: what is the evidence? Drugs Aging 2009;26:295-320.
14. Patel PJ, Bunce C, Tufail A. A randomised, double-masked phase III/ IV study of the efficacy and safety of avastin(R) (bevacizumab) intravitreal injections compared to standard therapy in subjects with choroidal neovascularisation secondary to age-related macular degeneration: clinical trial design. Trials 2008;9:56.
15. Antiplatelet Trialists' Collaboration. Collaborative overview of randomised trials of antiplatelet therapy - I: prevention of death, myocardial infarction, and stroke by prolonged antiplatelet therapy in various categories of patients. BMJ 1994;308:81-106.
16. Patel PJ, Chen FK, Rubin GS, Tufail A. Intersession repeatability of visual acuity scores in age-related macular degeneration. Invest Ophthalmol Vis Sci 2008;49:4347-52.
17. Dafer RM, Schneck M, Friberg TR, Jay WM. Intravitreal ranibizumab and bevacizumab: a review of risk. Semin Ophthalmol 2007;22:201-4. (Pubitemid 47346972)
18. Gillies MC, Wong TY. Ranibizumab for neovascular age-related macular degeneration. N Engl JMed 2007;356:748-9.
19. Bashshur ZF, Schakal A, Hamam RN, El Haibi CP, Jaafar RF, Noureddin BN. Intravitreal bevacizumab vs verteporfin photodynamic therapy for neovascular age-related macular degeneration. Arch Ophthalmol 2007;125:1357-61. (Pubitemid 47606600)
20. Giansanti F, Virgili G, Bini A, Rapizzi E, Giacomelli G, Donati MC, et al. Intravitreal bevacizumab therapy for choroidal neovascularization secondary to age-related macular degeneration: 6-month results of an open-label uncontrolled clinical study. Eur J Ophthalmol 2007;17:230-7.
21. Bashshur ZF, Bazarbachi A, Schakal A, Haddad ZA, El Haibi CP, Noureddin BN. Intravitreal bevacizumab for the management of choroidal neovascularization in age-related macular degeneration. Am J Ophthalmol 2006;142:1-9.
22. Lazic R, Gabric N. Intravitreally administered bevacizumab (avastin) in minimally classic and occult choroidal neovascularization secondary to age-related macular degeneration. Graefes Arch Clin Exp Ophthalmol 2007;245:68-73.
23. Pedersen KB, Sjolie AK, Moller F. Intravitreal bevacizumab (avastin) for neovascular age-relatedmacular degeneration in treatment-naive patients. Acta Ophthalmol 2008 Dec 16 (epub ahead of print).
24. Rich RM, Rosenfeld PJ, Puliafito CA, Dubovy SR, Davis JL, Flynn HWJr, et al. Short-term safety and efficacy of intravitreal bevacizumab (avastin) for neovascular age-related macular degeneration. Retina 2006;26:495-511.
25. Center for Preventive Opthalmology and Biostatistics. Comparison of age-related macular degeneration treatments trials. 2009. www. med.upenn.edu/cpob/studies/CATT.shtml.
26. CTEU Bristol. The IVAN trial. 2009. www.ivan-trial.co.uk/.
27. Costa RA, Jorge R, Calucci D, Melo LA Jr, Cardillo JA, Scott IU. Intravitreal bevacizumab (avastin) in combination with verteporfin photodynamic therapy for choroidal neovascularization associated with age-related macular degeneration (IBeVe Study). Graefes Arch Clin Exp Ophthalmol 2007;245:1273-80.
28. Azad R, Chandra P, Gupta R. The economic implications of the use of anti-vascular endothelial growth factor drugs in age-related macular degeneration. Indian J Ophthalmol 2007;55:441-3.
29. Steinbrook R. The price of sight - ranibizumab, bevacizumab, and the treatment of macular degeneration. N Engl J Med 2006;355:1409-12.
30. Wong TY, Liew G, Mitchell P. Clinical update: new treatments for age-related macular degeneration. Lancet 2007;370:204-6.
31. Rosenfeld PJ. New treatments for age-related macular degeneration. Lancet 2007;370:1479.
32. Taylor HR, Pezzullo ML, Guymer R. New treatments for age-related macular degeneration. Lancet 2007;370:1481.
33. Wagle AM, Yeo TK, Au Eong KG. New treatments for age-related macular degeneration. Lancet 2007;370:1481.
34. Raftery J, Clegg A, Jones J, Tan SC, Lotery A. Ranibizumab (lucentis) versus bevacizumab (avastin): modelling cost effectiveness. Br J Ophthalmol 2007;91:1244-6.